The disclosure relates to pharmaceutical combinations comprising an HDAC6 selective inhibitor and a BET inhibitor for the treatment of cancer in a subject in need thereof. Also provided herein are methods for treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of an HDAC6 selective inhibitor and a BET inhibitor.本發明係關於用於治療有需要個體癌症的包含HDAC6選擇性抑制劑及BET抑制劑之醫藥組合。本發明亦提供用於治療有需要個體之癌症之方法,該等方法包含向該個體投與有效量之HDAC6選擇性抑制劑及BET抑制劑。